-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

Benzinga·05/18/2026 15:06:50
Listen to the news
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.